LUNG · Insider Trading
Pulmonx Corporation Common Stock
Every open-market purchase and sale reported by LUNG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Srikanth Radhakrishnan | Chief Science & Techn. Officer | Sell | −14,245 | −$32.19K |
| 2026-09-03 | Geoffrey Beran Rose | Chief Commercial Officer | Sell | −7,879 | −$17.81K |
| 2026-09-03 | Glendon E. French III | President and CEO | Sell | −41,882 | −$94.65K |
| 2026-09-03 | David Aaron Lehman | General Counsel | Sell | −14,334 | −$32.39K |
| 2026-06-09 | Richard Ferrari | Director | A | +40,000 | — |
| 2026-06-09 | Dana G Mead Jr. | Director | A | +40,000 | — |
| 2026-06-09 | Daniel P Florin | Director | A | +40,000 | — |
| 2026-06-09 | Tiffany Sullivan | Director | A | +40,000 | — |
| 2026-06-09 | Georgia Melenikiotou | Director | A | +40,000 | — |
| 2026-06-09 | Thomas William Burns | Director | A | +40,000 | — |
| 2026-06-03 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sell | −8,023 | −$12.36K |
| 2026-06-03 | Glendon E. French III | President and CEO | Sell | −56,149 | −$86.87K |
| 2026-06-03 | David Aaron Lehman | GENERAL COUNSEL | Sell | −14,594 | −$22.47K |
| 2026-06-03 | Srikanth Radhakrishnan | Chief Science &Techn. Officer | Sell | −14,497 | −$22.33K |
| 2026-03-04 | David Aaron Lehman | GENERAL COUNSEL | MIXED | +137,763 | −$17.50K |
| 2026-03-04 | Srikanth Radhakrishnan | Chief Science &Techn. Officer | MIXED | +164,517 | −$14.99K |
| 2026-03-04 | Glendon E. French III | President and CEO | Sell | −67,813 | −$96.97K |
| 2026-03-04 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | MIXED | +92,268 | −$11.06K |
| 2025-12-09 | Daniel P Florin | Director | Sell | −23,321 | −$46.41K |
| 2025-12-03 | Derrick Sung | COO and CFO | A | +1,200,000 | — |
| 2025-12-03 | David Aaron Lehman | GENERAL COUNSEL | Sell | −10,278 | −$16.14K |
| 2025-12-03 | Glendon E. French III | President and CEO | MIXED | +1,191,195 | −$13.82K |
| 2025-12-03 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sell | −6,322 | −$9.93K |
| 2025-09-03 | Mehul Joshi | Chief Financial Officer & PAO | Sell | −7,936 | −$12.70K |
| 2025-09-03 | David Aaron Lehman | GENERAL COUNSEL | Sell | −9,769 | −$15.63K |
| 2025-09-03 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sell | −6,543 | −$10.47K |
| 2025-09-03 | Steven S. Williamson | PRESIDENT AND CEO | Sell | −9,648 | −$15.44K |
| 2025-06-13 | Richard Ferrari | Director | Sell | −8,000 | −$25.28K |
| 2025-06-05 | Daniel P Florin | Director | Buy | +23,321 | +$71.36K |
| 2025-06-04 | Daniel P Florin | Director | A | +37,153 | — |
| 2025-06-04 | Thomas William Burns | Director | A | +37,153 | — |
| 2025-06-04 | David Aaron Lehman | GENERAL COUNSEL | Sell | −10,457 | −$32.74K |
| 2025-06-04 | Tiffany Sullivan | Director | A | +37,153 | — |
| 2025-06-04 | Georgia Melenikiotou | Director | A | +37,153 | — |
| 2025-06-04 | Steven S. Williamson | PRESIDENT AND CEO | Sell | −9,923 | −$31.06K |
| 2025-06-04 | Richard Ferrari | Director | A | +37,153 | — |
| 2025-06-04 | Mehul Joshi | Chief Financial Officer & PAO | Sell | −8,061 | −$25.23K |
| 2025-06-04 | Dana G Mead Jr. | Director | A | +37,153 | — |
| 2025-06-04 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sell | −6,947 | −$21.75K |
| 2025-06-04 | Glendon E. French III | Director | A | +37,153 | — |
| 2025-03-21 | Glendon E. French III | Director | Sell | −20,000 | −$157.00K |
| 2025-03-05 | Mehul Joshi | Chief Financial Officer & PAO | MIXED | +93,616 | −$102.41K |
| 2025-03-05 | Steven S. Williamson | PRESIDENT AND CEO | MIXED | +154,007 | −$197.70K |
| 2025-03-05 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | MIXED | +102,221 | −$41.19K |
| 2025-03-05 | David Aaron Lehman | GENERAL COUNSEL | MIXED | +85,645 | −$170.92K |
| 2025-02-24 | Glendon E. French III | Director | Sell | −55,453 | −$459.09K |
| 2025-01-21 | Glendon E. French III | Director | Sell | −4,547 | −$29.63K |
| 2024-12-04 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sell | −4,376 | −$27.07K |
| 2024-12-04 | David Aaron Lehman | GENERAL COUNSEL | Sell | −5,497 | −$34.01K |
| 2024-11-26 | Glendon E. French III | Director | Sell | −20,000 | −$132.60K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Glendon E. French III | President and CEO | 2,093,918 | $4.04M |
| Richard Ferrari | Director | 1,359,345 | $2.62M |
| Derrick Sung | COO and CFO | 1,335,319 | $2.58M |
| Geoffrey Beran Rose | Chief Commercial Officer | 451,578 | $871.55K |
| David Aaron Lehman | General Counsel | 372,354 | $718.64K |
| Steven S. Williamson | PRESIDENT AND CEO | 363,497 | $701.55K |
| Srikanth Radhakrishnan | Chief Science & Techn. Officer | 316,994 | $611.80K |
| Mehul Joshi | Chief Financial Officer & PAO | 212,154 | $409.46K |
| Daniel P Florin | Director | 149,699 | $288.92K |
| Dana G Mead Jr. | Director | 143,790 | $277.51K |
| Georgia Melenikiotou | Director | 139,714 | $269.65K |
| Tiffany Sullivan | Director | 115,199 | $222.33K |
| Thomas William Burns | Director | 113,399 | $218.86K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LUNG quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.